MSMurat Söker

Murat Söker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Murat Söker has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Characteristics and Treatment Patterns in Children with Sickle Cell Anemia in Southeastern Türkiye: A Retrospective Single-Center Study

    by Veysiye Hülya Üzel, Murat Söker

    Background/Objectives: We aimed to describe clinical burden, treatment patterns, and reported adherence in children with presumed HbSS in Southeastern Türkiye. Methods: This retrospective single-center study included 41 children with sufficient clinical records covering 2011–2021; the retrospective chart review was conducted in 2025, and clinical events after 2021 were not included. Diagnosis was supported by hemoglobin electrophoresis at presentation to our center and parental electrophoresis results. Complete molecular records were unavailable. Annual pain-crisis frequency was the average of hospital-documented events over follow-up. Results: There were 24 girls and 17 boys; mean age at last assessment was 9.49 ± 4.55 years. Fifteen children (36.6%) averaged ≥3 pain crises/year. Hydroxyurea had been prescribed to 38 children: 34 reported regular use and four adolescents reported irregular use at the last assessment. Three two-year-old children had not started treatment. The ≥3-crises/year category included 8/34 regular users, 4/4 irregular users, and 3/3 untreated children. An exploratory comparison among prescribed patients yielded a two-sided Fisher exact p-value of 0.0067. No hematologic toxicity requiring dose reduction or treatment discontinuation was documented. Eight children received chronic transfusions and deferasirox. Acute chest syndrome and ischemic stroke were documented in three and two children, respectively. Conclusions: This series distinguishes treatment prescription, reported regular use, and age-related non-initiation within a population with ongoing morbidity. The different timeframes for adherence and crisis assessment and the small subgroups preclude causal interpretation of treatment effects.

  • Open Access

    Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association

    by Yeter Düzenli Kar, Hale Ören, Melike Sezgin Evim, Emine Zengin, Ekin Gün, Nihal Karadaş, Deniz Yılmaz Karapınar, Canan Albayrak, Selma Ünal, Feryal Karahan, et al.

  • Open Access

    Retrospective analysis of demographic and clinical characteristics and treatment outcomes of pediatric acute lymphoblastic leukemia patients

    by Murat Solmaz, Murat Söker, Veysiye Hülya Üzel, Sevda Söker, Kahraman Öncel, Kamil Yilmaz

    Aim: This study aimed to compare treatment outcomes (mortality and relapse) between two pediatric acute lymphoblastic leukemia (ALL) protocols (TR-ALL BFM 2000 vs ALL-IC-BFM 2009) and to describe the demographic, clinical, and laboratory characteristics of patients treated at a single center (2010–2015). Methods: We retrospectively reviewed the medical records of 121 children (<18 years) diagnosed with ALL and treated with either TR-ALL BFM 2000 or ALL-IC-BFM 2009. Baseline characteristics, risk group, immunophenotype, protocol, relapse status, and survival status were recorded. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate (p < 0.05). Results: The cohort was 53.7% male, with a mean age at diagnosis of 7.55 ± 3.89 years. B-cell ALL accounted for 78.5% and T-cell ALL for 21.5%. The overall mortality rate was 11.6% (14/121), and relapse occurred in 5.8% (7/121) of patients. Mortality differed by risk group (SRG 6.5%, IRG 7.3%, HRG 23.5%; p = 0.036). Relapse was higher in T-cell ALL than in B-cell ALL (23.1% vs 1.1%; p = 0.001). Compared with ALL-IC-BFM 2009, TR-ALL BFM 2000 was associated with higher mortality (19.2% vs 5.8%; p = 0.022) and relapse (11.5% vs 1.4%; p = 0.019). Conclusion: In this single-center retrospective cohort study, the high-risk group was associated with higher mortality, and the T-cell immunophenotype was associated with higher relapse. Patients treated with ALL-IC-BFM 2009 had lower crude mortality and relapse rates than those treated with TR-ALL BFM 2000; however, these protocol comparisons should be interpreted cautiously, given potential confounding and limited event numbers.


  • Evaluation of retinal nerve fiber layer and choroidal thickness with spectral domain optical coherence tomography in children with sickle cell anemia

    by Kamil Yılmaz, Hasan Öncül, Hülya Uzel, Kahraman Öncel, E Deniz Yılmaz, Murat Söker

    Background. The aim of this study is to examine the thickness of choroidal, macular and peripapillary retinal nerve fiber layer by spectral-domain optical coherence tomography (SD-OCT) in pediatric patients with sickle cell anemia (SCA) without retinopathy. Methods. A total of 75 children (30 SCA patients (Group 1) and 45 healthy individuals (Group 2) were included in the study. Macular (central, superior, inferior, nasal, temporal), choroidal (subfoveal, at nasal distances from the central fovea of 1000 μm [N1], 2000 μm [N2], 3000 μm [N3], at temporal distances from the central fovea of 1000 μm [T1], 2000 μm [T2], 3000 μm [T3]) and RNFL (average, temporal, superotemporal, inferotemporal, nasal, inferonasal and superonasal) measurements were performed by SD-OCT. These parameters were compared with healthy children with similar demographic characteristics. Results. The mean age was 14.11±3.86 (11-18) in sickle cell anemia patients and 13.15± 2.69 (10-18) in the healthy control group. Of the patients, 56.6% (n=17) of Group 1 and 44.4% (n=20) of Group 2 were male. Choroidal measurements made in the subfoveal, N1, N2, N3, T1, T2 and T3 quadrants showed that the choroid was thinner in 6 quadrants in SCA patients compared to the healthy group (p = 0.003, p = 0.039, p = 0.035, p = 0.595, p = 0.006, p = 0.005, p = 0.047, respectively). In RNFL measurements, there was significant thinning in the temporal, inferotemporal, and nasal quadrants of SCA patients compared to the healthy group. Changes in other quadrants were not significant. Conclusions. SD-OCT is a useful imaging method in the diagnosis and screening in patients with SCA without retinopathy. Early diagnosis of retinopathy during subclinical disease will prevent visual loss in these patients.


  • Open Access

    Evaluation of 36 Patients with Rare Factor Deficiency

    by Veysiye Hülya Üzel, Kamil Yılmaz, Kahraman Öncel, Suat Tekin, Murat Söker


  • Open Access

    Comparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasirox

    by Tekin Aksu, Namık Yaşar Özbek, Murat Söker, Çağrı Coşkun, Zeliha Güzelküçük, Hülya Veysiye Üzel, Neşe Yaralı, Fatma Gümrük, Şule Ünal

    Objective: The current iron chelation therapy regimens include deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) in transfusion-dependent patients. Compliance with iron-chelating therapy is one of the significant determinants of mortality and morbidities related to iron loading in chronically transfused patients. This survey aims to compare the compliance and the satisfaction of DFO, DFP, and DFX formulations in patients who have iron-overloading in three hematology centers from Turkey. Moreover, bioequivalent (generic) formulations of dispersible DFX tablet compared with the original formulation in terms of taste and treatment compliance. Patients and Methods: A written questionnaire with a list of pre-set questions was applied to measure patient-reported outcomes to a total of 85 patients, where 77 had beta-thalassemia major, 7 had beta-thalassemia intermedia, and 1 had sickle cell anemia diagnoses. Results: The patients’ median age at enrollment was 15 years (range 7 – 42). The compliance was below 50% in 8 (18.6%), 4 (16%), and 5 (6.7%) in patients receiving DFO, DFP, and DFX, respectively. Additionally the compliance was below 80% in 16 (37.2%), 9 (36%), and 17 (22.6%) in patients receiving DFO, DFP, and DFX, respectively. It was found that 39 (47%) patients had compliance problems due to the dispersible DFX tablet formulations’ taste, except combination therapies. There was no difference between the currently used oral chelators in terms of taste and treatment compliance. Conclusion: This study draws attention to compliance problems in patients with iron-loading anemias, partly due to the unpleasant taste of DFX. Improving patient satisfaction and compliance with iron-chelator therapy may reduce complications of iron overload.


  • Open Access

    OUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY

    by Ayça Koca Yozgat, Göksel Leblebisatan, Sinan Akbayram, Simge Çınar Özel, Zeynep Karakaş, Erol Erduran, Şebnem Yılmaz, Ülker Koçak, Şule Ünal, Gül Nihal Özdemir, et al.

    Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.


  • Open Access

    Fertility in Patients with Thalassemia and Outcome of Pregnancies: a Turkish Experience

    by Burcu Akıncı, Akkız Sahin Yasar, Nihal Özdemir Karadas, Zuhal Önder Sivis, Hamiyet Hekimci Özdemir, Deniz Yılmaz Karapinar, Can Balkan, Kaan Kavakli, Yesim Aydinok

    Objective: In recent years, the rates of marriage and pregnancy are increasing in patients with thalassemia major. The aim of the present study was to investigate the fertility rate of thalassemic patients and the course of pregnancies in terms of mother and infant health. Materials and Methods: In this observational study patients with major hemoglobinopathy were evaluated regarding marital status, the need for assisted reproductive techniques, fertility rate, iron status, and pregnancy complications. Results: Seventeen female patients gave birth to 21 healthy infants. About one-third of the patients needed assisted reproductive techniques. Thalassemia major patients showed increased serum ferritin levels from 1203 +/- 1206 mu g/L. at baseline to 1880 +/- 1174 mu g/L at the end of pregnancy. All babies are still alive and healthy. Conclusion: Pregnancy in patients with thalassemia can be safe for the mother and newborn with close monitoring and a multidisciplinary approach.


  • MRI-based evaluation of the factors leading to pituitary iron overload in patients with thalassemia major

    by Mehmet Güli Çetinçakmak, Salih Hattapoğlu, Sait Menzilcioğlu, Bircan Alan, Ünal Uluca, Ahmet Uçar, Murat Söker, Aslan Bilici


  • Open Access

    A Rare Cause of Recurrent Oral Lesions: Chediak- Higashi Syndrome

    by Müsemma Karabel, Selvi Kelekçi, Velat Şen, Duran Karabel, Çiğdem Aliosmanoğlu, Murat Söker